Associations between hepatocyte growth factor, c-Met and basic fibroblast growth factor and survival in endometrial cancer patients

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

(2011) C. Lieu et al.   CLINICAL CANCER RESEARCH

Therapeutic targeting of tumor–stroma interactions

(2011) Stephen Hiscox et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma

(2010) Hanan AlSaeid Alshenawy   Annals of Diagnostic Pathology

Factors associated with Type I and Type II endometrial cancer

(2010) Ashley S. Felix et al.   CANCER CAUSES & CONTROL

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

(2010) M. S. Gordon et al.   CLINICAL CANCER RESEARCH

The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma

(2010) Erin A. Bishop et al.   GYNECOLOGIC ONCOLOGY

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

(2010) Sigve Andersen et al.   Journal of Thoracic Oncology

Targeting the HGF/c-Met Axis: State of Play

(2010) T. A. Yap et al.   MOLECULAR CANCER THERAPEUTICS

Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer

(2008) C. Behrens et al.   CLINICAL CANCER RESEARCH

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY